SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses its potential, highlighting its speed and efficiency compared to other blockchains like Ethereum. Discussions also involve meme coins built on Solana, with some users anticipating a strong rally. Additionally, the recent Alpenglow upgrade, aimed at boosting transaction speeds, has generated buzz.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

$SNAP is trending as traders discuss potential catalysts including AI integration, a possible buyout, and speculation around increased interest from Reddit's WallStreetBets community. Community members are actively debating price targets, potential acquirers, and the impact of AI on the platform's future, while also noting the stock's high short interest and recent trading volume.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending as the FDA considers the ineffectiveness of phenylephrine, an ingredient in popular decongestants like Sudafed PE, potentially impacting sales. Despite this, some analysts remain bullish, citing attractive entry points and a recent addition to the S&P 500, with the community actively monitoring price movements for potential buying opportunities.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is trending amid discussions around its correlation to crypto markets and AI data center prospects, with some traders expressing frustration over its price action and potential manipulation. Community members are debating its valuation and future performance, particularly in relation to upcoming earnings and Helios updates. Bearish sentiment is emerging with some traders targeting lower price points.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to a recent analyst downgrade impacting investor sentiment, while some community members view the dip as a buying opportunity. Community talking points include the sustainability of AMD's growth, competition with NVIDIA and Broadcom, and potential price targets. Despite the selloff, some express confidence in AMD's long-term prospects, particularly in the AI and data center markets.

Krypto Cock is a meme-powered crypto project with real onchain utility. Born from the lessons of past market cycles, $COCK blends humor, culture, and technology to create a unique community-driven ecosystem.  The project is focused on: • Building lightweight mini-apps for Farcaster and other onchain platforms • Developing an engaged, growing community • Delivering consistent, high-quality content • Offering practical onchain tools and experiences • Led by a team with years of crypto and product experience  $COCK aims to make the crypto experience more fun, accessible, and connected, without sacrificing purpose or quality.

CockCardano

$COCK.X is trending as the community rallies around the upcoming launch of Cocky Wings LLC, a real-world food business associated with the Cardano-based meme coin. Community members highlight the potential for passive income through staking and are excited about the partnership with $SNEK.X and the presence at the South Carolina Gamecocks home game.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions about the Epstein files and Trump's potential involvement, with some users calling for their release while others defend him. Community members are also debating the stock's valuation and the broader implications of Trump's policies on the economy and international relations. The stock is highly divisive, with many users expressing strong opinions for and against Trump and his company.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending due to recent bullish momentum and community excitement around upcoming airdrops and staking. The community believes $BROKE has strong long-term potential, citing the active developer, engaged community, and plans for future utilities as reasons for its upward trajectory. Many community members are actively participating in a buy contest, and anticipating a new ATH.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending amid high trading volume and social media buzz, with community members actively discussing potential short squeezes and a climb towards a target price of $10. Speculation around upcoming news, such as a new CEO announcement, and broader market factors, like potential interest rate cuts, appear to be fueling optimism. Despite some bearish sentiment and a recent critical report from Citron Research, many investors express confidence in OPEN's long-term potential.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

MSFT is trending due to discussions around potential AI competition and overall market performance following key earnings reports. Community members are weighing the stock's value compared to other tech giants, with some eyeing potential options plays and reversals, while others express concern over its recent underperformance and downward momentum. The conversation includes speculation about factors influencing the stock's price, ranging from CEO share sales to broader economic indicators.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evoke Pharma's stock soared 168% on Wednesday after the company announced it had received a new U.S. patent that could extend the market life of Gimoti, its nasal spray treatment for gastroparesis.The patent, once issued, would provide Evoke with added protection through December 2036, covering the use of the drug in patients with moderate to severe symptoms of the condition.&nbsp;Gastroparesis impairs the stomach’s ability to empty, often rendering oral medications less effective.&nbsp;Evoke plans to list the new patent in the FDA’s Orange Book, which would extend exclusivity for Gimoti beyond its current timeline.The news comes alongside improving financials. In the first quarter of 2025, Evoke generated approximately $3.1 million in product sales, nearly doubling its revenue from the same period a year earlier.&nbsp;The company reported a net loss of $1.3 million, which&nbsp;translates to a loss of $0.51 per share, representing an improvement from the $1.6 million loss, or $2.09 loss per share, in the same quarter last year.Spending also ticked up, driven mainly by higher fees and profit-sharing with Eversana, its commercial partner.&nbsp;Operating expenses totaled $4.4 million, up from $3.2 million a year earlier.As of March 31, Evoke had $12.6 million in cash.&nbsp;Based on its current plans, it expects to carry operations into the second quarter of 2026.&nbsp;The company is also sticking to its 2025 sales goal of $16 million, which would be a 60% increase from last year if current trends continue.On Stocktwits, retail sentiment for Evoke was ‘extremely bullish’ amid ‘extremely high’ message volume.One user mentioned buying 100 lots of Evoke’s stock and said they were waiting for a potential move to cover.&nbsp;<stembedurl>https://stocktwits.com/mikefromclt/message/620413256</stembedurl>Another user expressed a bullish outlook as well, saying they were fully loaded on the stock and planned to hold their position into the next session.<stembedurl>https://stocktwits.com/stocksweets/message/620411085</stembedurl><a href="https://stocktwits.com/symbol/EVOK">Evoke’s stock</a> has risen 56.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Evoke Pharma (EVOK) received a new U.S. patent that could extend the market life of Gimoti/ Photo credit: Getty Images

Evoke Pharma Stock Skyrockets On Patent For Nasal Spray That Eases Stomach Delays; Retail Bulls Pile In

The newly allowed patent covers the use of Gimoti in patients with moderate to severe gastroparesis and is expected to extend market exclusivity through 2036. 

Equity

Evoke shares drop 15% as loss widens despite revenue growth

Evoke expects earnings to exceed market expectations, shares jump

Monte Rosa Therapeutics Inc. (<a class="mention" data-mention="$GLUE" data-symbol-id="GLUE" href="https://stocktwits.com/symbol/GLUE" target="_blank">$GLUE</a>)<figure class="image"><a href="https://stocktwits.com/symbol/GLUE"><img style="aspect-ratio:1284/287;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132438_e581646ba1.png" alt="Screenshot 2024-10-28 132438.png" width="1284" height="287"></a><figcaption>Monte Rosa Therapeutic's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Monte Rosa Therapeutics surged over 130% on Monday, reaching a two-year high of $12.15 after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-enthralls-retail-with-novartis-licensing-deal/cJ2rnM9RJW">announcing an exclusive global licensing agreement with Novartis AG ($NVS).</a>&nbsp;The collaboration focuses on developing innovative treatments for immune-related conditions, particularly MRT-6160, an oral drug designed to inhibit the degradation of VAV1, a key signaling protein for T and B cell receptors.&nbsp;As part of the agreement, Novartis will pay $150 million upfront for exclusive worldwide rights to MRT-6160 and other VAV1-targeting molecular glues, with Monte Rosa eligible for up to $2.1 billion in milestones and tiered royalties on international sales.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with ‘extremely high’ (97/100) message volume.Evoke Pharma Inc. (<a class="mention" data-mention="$EVOK" data-symbol-id="EVOK" href="https://stocktwits.com/symbol/EVOK" target="_blank">$EVOK</a>)<figure class="image"><a href="https://stocktwits.com/symbol/EVOK"><img style="aspect-ratio:1282/282;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132459_473ee74b09.png" alt="Screenshot 2024-10-28 132459.png" width="1282" height="282"></a><figcaption>Evoke Pharma's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Evoke Pharma’s shares were up over 30% on Monday following its presentation of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/evoke-pharma-stock-spikes-higher-on-study-data/cJ2rllaRJO">positive data for its lead drug</a>, Gimoti, as a treatment option for diabetes gastroparesis.The company ranked among the top 10 trending stocks on Stocktwits, secured the second spot for most watched, and was listed in the top 20 most active stocks&nbsp;on Monday afternoon.Evoke Pharma and its partner, Eversana, found that patients using Gimoti, a nasal version of metoclopramide, experienced significant improvements compared to those using the oral formulation. Patients who received the nasal treatment had reduced healthcare resource use and fewer healthcare visits.Retail sentiment on Stocktwits surged into ‘extremely bullish’ territory (97/100) with ‘extremely high’ (97/100) message volume.Autonomix Medical Inc. (<a class="mention" data-mention="$AMIX" data-symbol-id="AMIX" href="https://stocktwits.com/symbol/AMIX" target="_blank">$AMIX</a>)<figure class="image"><a href="https://stocktwits.com/symbol/AMIX"><img style="aspect-ratio:1271/277;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132518_8d6392edf1.png" alt="Screenshot 2024-10-28 132518.png" width="1271" height="277"></a><figcaption>Autonomix Medical's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Autonomix skyrocketed by more than 90% on Monday morning following the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/autonomix-stock-rallies-on-strong-trial-results/cJ2rlAHRJf">announcement of positive results from its clinical trial</a> aimed at alleviating pain in pancreatic cancer patients.&nbsp;The stock became the second-highest trending on Stocktwits, just behind Trump Media &amp; Technology Group Corp. ($DJT), and was listed among the top 10 most watched stocks of the day.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with chatter escalating into ‘extremely high’ (97/100) territory.For updates and corrections email newsroom@stocktwits.com.Read more: <a href="https://stocktwits.com/news-articles/markets/equity/mstr-stock-hits-all-time-high-as-btc-crosses-68000/cJ2rj2hRJ9">MicroStrategy’s Bitcoin Holdings Drive Historic High: Retail Unfazed</a>

Retail is most bullish on these stocks today | Source: Pexels

Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention

Retail sentiment was particularly strong for healthcare stocks today, as Monte Rosa, Autonomix, and Evoke Pharma each announced positive developments regarding their respective innovations.

Shares of nano-cap specialty biopharma Evoke Pharma, Inc. ($EVOK) skyrocketed on Monday following its presentation of positive data for its lead drug Gimoti as a treatment option for diabetes gastroparesis.Solana Beach, California-based Evoke said on Monday that it along with its Eversana, a provider of global commercial services to the life sciences industry, presented data for GLP-1 users with diabetic gastroparesis using Gimoti at the 2024 American College of Gastroenterology annual meeting.The real-world retrospective study that evaluated the impact of Gimoti showed significant reductions across a collection of outcomes observed in patients treated with Gimoti, a nasal formulation of metoclopramide, versus oral formulation of the same, Evoke Pharma said.Patients taking nasal formulation had reduced healthcare resource utilization, and fewer healthcare visits."Our goal is to provide data regarding Gimoti as supportive care for diabetic gastroparesis for those also on GLP-1 agonists. This study, combined with the earlier real-world data presented at key conferences, reinforces GIMOTI's potential to improve outcomes for patients and reduce the overall financial burden on the healthcare system,” said Matt D’Onofrio, CEO of Evoke Pharma.<figure class="image"><a href="https://stocktwits.com/symbol/EVOK"><img style="aspect-ratio:632/132;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/evok_sentiment_973d4ea465.png" alt="evok-sentiment.png" width="632" height="132"></a><figcaption>EVOK sentiment and message volume October 28, 2024, as of 11:05 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Amid the stock rally, retail sentiment toward the stock improved from ‘neutral’ a day ago to ‘extremely bullish’ (97/100) on Monday morning, with message volume spiking to ‘extremely high.’Some among the retail crowd cautioned against selling the stock and said it is worth much more than the level at which it currently traded.<stembedurl>https://stocktwits.com/Shieldsstocks/message/590294090</stembedurl>Gimoti received FDA approval as an option of alleviating symptoms in adults with acute and recurrent diabetic gastroparesis in June 2020.In the second-quarter ended June 30, 2024, Gimoti sales climbed 126% year-over-year and 47% sequentially to $2.55 million. At that time, the company revised up its 2024 net sales guidance from $11 million-$12 million to $14 million, citing the trend seen in the first half of the year.As of 11:05 a.m. ET, Evoke Pharms shares climbed 67.55% to $3.58.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/five-magnificent-seven-companies-are-due-to-release-their-quarterly-score-cards-this-week/cJ2riJORJJ">Apple, Microsoft, Google, Meta, Amazon: How’s Retail Feeling About These Big Tech Stocks Ahead Of Earnings This Week?</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

Evoke pharma presentation of real-world data for Gimoti at a conference sent its shares soaring.

Evoke Pharma's Retail Sentiment Soars As Stock Rockets On Promising Real-World Data For Gastric Disorder Drug

The real-world retrospective study that evaluated the impact of Gimoti showed significant reductions across a collection of outcomes observed in patients treated with Gimoti.

Evoke Pharma Stock Is Soaring Monday: What's Going On?

Evoke Pharma Inc (NASDAQ:EVOK) shares are trading higher Monday after the company presented GLP-1 data for users with diabetic gastoparesis using GIMOTI showing statistically significant...

Why Evoke Pharma (EVOK) Stock Is Volatile

Evoke Pharma shares were trading lower by 21.4% during Tuesday's session. The company announced a 1-for-12 reverse stock split of its common stock.
read more...

12 titoli sanitari in movimento, pre-market del 10/04/2024

Titoli in rialzo
Il titolo Evoke Pharma (NASDAQ:EVOK) ha osservato un incremento del 41,47% a 0,75 dollari durante la sessione pre-market di mercoled .
Le azioni di Jaguar Health (NASDAQ:JAGX) sono...

StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK)

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK - Free Report) in a report issued on Tuesday. The firm issued a sell rating on the specialty pharmaceutical company's stock...

Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK - Free Report) in a research report sent to investors on Tuesday morning. The firm issued a sell rating on the specialty...

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Evoke Pharma Inc

$APP

$MSTR

$HOOD

other (drop a comment)

The S&amp;P 500 rebalance announcement is today — which stock do you think has the best shot at getting added?

Current Price	$5.22
Prev Close	$5.29
Open	$5.22
Dividend Yield	0.00%
50-Day Moving Average	$4.73
Beta	0.52
Avg. Volume	473,426.43
PE Ratio	-1.84

52-Week High	$12.32
52-Week Low	$1.94
Market Capitalization	$8.24M
EPS (Annual)	-$2.81
Price to Book	1.81
Revenue Per Employee	$3.42M
Enterprise Value/EBITDA	N/A

EVOK
Evoke Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EVOK News

EVOK Evoke Pharma Inc